文献速递小儿眼科与斜弱视

弱视治疗新进展I:双眼疗法与药物增强

New advances in amblyopia therapy I: binocular therapies and pharmacologic augmentation.
PubMed 文献 · Br J Ophthalmol · 2018-05-18

本文综述了弱视治疗的传统方法(遮盖、药物抑制、眼镜)及新兴的双眼治疗(知觉学习、iPad双眼分视训练)和药物增强策略。现有证据显示尚无新疗法优于传统疗法,但新技术与神经机制研究为未来替代或更优治疗带来希望。

要点

  • 传统疗法包括遮盖、阿托品药物抑制和单独配镜,后者已确立为屈光参差性和斜视性弱视的一线治疗。
  • iPad双眼分视训练和知觉学习在弱视视力改善方面产生了有趣且有前景的数据。
  • 多种不同作用机制的药物被认为可神经敏化大脑并增强对弱视治疗的反应。

核心结论

  • 现有证据中尚无新疗法在临床实践中优于传统疗法。
  • 对新技术和弱视神经基础的研究有望在未来带来替代或更好的治愈方法。

研究设计与样本

  • 本文为综述,未报告系统检索范围。

主要发现

  • 传统弱视治疗选项限于遮盖或药物抑制非弱视眼。
  • 来自Pediatric Eye Disease Investigator Group的坚实证据验证了每日遮盖小时数和每周阿托品使用天数。
  • 单独使用眼镜已确立为屈光参差性和斜视性弱视的良好一线治疗。
  • 视力均衡或改善并非总能通过这些方法实现,且不依从处方治疗导致治疗失败。
  • 知觉学习早期工作及近期对iPad双眼分视训练的热情均产生了有趣且有前景的弱视视力改善数据。

临床怎么用

  • 传统疗法(遮盖、阿托品、眼镜)仍是当前临床实践中的标准治疗。
  • 双眼治疗和药物增强尚未被证据证明优于传统疗法,但可作为研究性选择考虑。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Amblyopia therapy options have traditionally been limited to penalisation of the non-amblyopic eye with either patching or pharmaceutical penalisation. Solid evidence, mostly from the Pediatric Eye Disease Investigator Group, has validated both number of hours a day of patching and days per week of atropine use. The use of glasses alone has also been established as a good first-line therapy for both anisometropic and strabismic amblyopia. Unfortunately, visual acuity equalisation or even improvement is not always attainable with these methods. Additionally, non-compliance with prescribed therapies contributes to treatment failures, with data supporting difficulty adhering to full treatment sessions. Interest in alternative therapies for amblyopia treatment has long been a topic of interest among researchers and clinicians alike. Incorporating new technology with an understanding of the biological basis of amblyopia has led to enthusiasm for binocular treatment of amblyopia. Early work on perceptual learning as well as more recent enthusiasm for iPad-based dichoptic training have each generated interesting and promising data for vision improvement in amblyopes. Use of pharmaceutical augmentation of traditional therapies has also been investigated. Several different drugs with unique mechanisms of action are thought to be able to neurosensitise the brain and enhance responsiveness to amblyopia therapy. No new treatment has emerged from currently available evidence as superior to the traditional therapies in common practice today. But ongoing investigation into the use of both new technology and the understanding of the neural basis of amblyopia promises alternate or perhaps better cures in the future.

来源:Br J Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Kraus CL, Culican SM. New advances in amblyopia therapy I: binocular therapies and pharmacologic augmentation. Br J Ophthalmol. 2018. PMID: 29777043. doi:10.1136/bjophthalmol-2018-312172

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。